En vivo
Thermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải PhòngFierceBiotechLilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitorsThermo FisherThermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.comWatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn LaFierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25BFierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BBioWorldAppointments and advancements for April 22, 2026BioWorldFinancings for April 22, 2026BioWorldIn the clinic for April 22, 2026BioWorldOther news to note for April 22, 2026
Endpoints News 6 feb 2026

Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis

Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis

Original
Contenido no disponible. Consulta la fuente original.